Events and Presentations

Franziska Buriánek, M.D., Senior Medical Director at Immunic, will present data from Immunic’s phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), in patients with celiac disease, in an oral presentation.

• Presentation Title: First In Human Trial Of IMU-856, An Orally Available Epigenetic Modulator Of Barrier Regeneration For The Treatment Of Celiac Disease
• Abstract ID: 4025905
• Session Title: Since Sliced Bread: Best in Celiac 2024
• Session Type: Research Forum
• Session Date: Monday, May 20, 2024
• Session Time: 2:00 - 3:30 pm EDT

Download Poster Presentation

1.1 MB